New GSK Spin-Out Targets Hearing Loss
This article was originally published in Start Up
The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.
You may also be interested in...
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.